0.00
+33.33%
Close of 9 Nov 2026, in AUD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Percheron Therapeutics
Its shares trade on ASX under the ticker PER.AX. It has been listed since 20 December 2001. In the fiscal year to 30 June 2023, it reported revenue of A$384,920 and a net loss of A$11.4m. At that date it held total assets of A$12.8m and shareholders' equity of A$10.0m.
Percheron Therapeutics Ltd is a AU-based company operating in Pharmaceuticals industry. The company is headquartered in Melbourne, Victoria. The company went IPO on 2001-12-20. Percheron Therapeutics Limited, formerly Antisense Therapeutics Limited, is a biotechnology company. The firm is engaged in developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The Company’s products include ATL1102 for Duchenne muscular dystrophy (DMD), ATL1103 for Acromegaly, and ATL1102 for Multiple Sclerosis (MS). ATL1102, is an antisense inhibitor targeting very late antigen 4 (VLA-4), an immune cell molecule. ATL1103 is a second-generation antisense drug designed to block growth hormone receptor (GHr) expression thereby reducing levels of the hormone insulin-like growth factor-I (IGF-I) in the blood and is a potential treatment for diseases associated with excessive growth hormone action. By inhibiting GHr production, ATL1103 in turn reduces IGF-I levels in the blood (serum). The firm is conducting a Phase II clinical trial of ATL1102 in DMD patients.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 20 Dec 2001
- Website
- antisense.com.au ↗
Leadership
Pay as last reported
- Dr. Charmaine GittlesonNon-Executive Independent Chairman of the Board, since 2021A$55,000
- Dr. James GarnerChief Executive Officer, Managing Director, Executive Director, since 2023
- Ms. Deborah AmbrosiniChief Financial Officer, Company Secretary
- Dr. Anthony FilippisChief Commercial Officer
- Dr. Andrew MckenzieClinical Development Director
- Dr. George TachasDirector - Drug Discovery and PatentsA$314,628
- Dr. Ben PriceNon-Executive Independent Director, since 2020A$113,274
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Percheron Therapeutics Ltd is a biotechnology company focused on developing antisense pharmaceuticals for rare diseases.
- The company has multiple product candidates including ATL1102 for Duchenne muscular dystrophy and ATL1103 for Acromegaly.
- Percheron Therapeutics Ltd has conducted a Phase II clinical trial for ATL1102 in Duchenne muscular dystrophy patients.
Weaknesses
- The company's website URL is listed as https://www.antisense.com.au/ which may not reflect current branding.
- The company was formerly known as Antisense Therapeutics Limited, indicating a possible rebranding or restructuring.
- The company's products are still in clinical development stages, with no commercialized products mentioned.
Opportunities
- The company targets large unmet markets in rare diseases, offering potential for significant market penetration.
- The development of ATL1102 for Duchenne muscular dystrophy aligns with ongoing research in rare disease treatments.
- The company's focus on antisense pharmaceuticals could benefit from advancements in biotechnology and drug delivery systems.
Threats
- The company's products are in clinical trials, which carry high risks of failure and regulatory hurdles.
- The pharmaceutical industry is highly competitive with significant research and development costs.
- The company's reliance on a limited number of product candidates increases vulnerability to clinical trial setbacks.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.